Peter Handrinos practices corporate and securities law, with an emphasis on mergers and acquisitions, capital markets, and venture capital transactions for life sciences and technology companies. Mr. Handrinos advises both public and private companies on a range of matters, including:
- Initial public offerings (IPO)
- Follow-on offerings
- Strategic investments
- 144A offerings
- Cash and stock mergers
- Tender offers
- Going-private transactions
He counsels numerous startup companies and venture capital firms in venture capital financings. Mr. Handrinos also regularly represents investment banks in connection with capital markets transactions. A significant portion of his practice involves general corporate work for ongoing clients on matters such as Securities and Exchange Commission compliance, securities and disclosure issues, and corporate governance matters.
The Legal 500 US describes Mr. Handrinos as “one of the best life sciences lawyers in Boston.” He has been recognized as a leader in Life Sciences and in Corporate/M&A by Chambers USA, where he is described as "extremely experienced" with "very valuable insights across critical financing and governance matters." Mr. Handrinos is recognized as a Life Sciences Star in the 2016 LMG Life Sciences Guide. He has also been listed in the 2012 through 2017 editions of Best Lawyers in America as a leader in mergers and acquisitions.
Mr. Handrinos has advised the following clients on their IPOs:
- Verona Pharma
- Selecta Biosciences
- Merus
- Seres Therapeutics
- Press Ganey
- Valeritas
- T2 Biosystems
- Radius Health
- BIND Therapeutics
- Aratana Therapeutics
Mr. Handrinos has advised the underwriters for the following IPOs:
- Aileron Therapeutics
- Ra Pharmaceuticals
- Kadmon Holdings
- Intellia Therapeutics
- Clearside Biomedical
- American Renal Associates
- Aclaris Therapeutics
- Blueprint Medicines Corporation
- CoLucid Pharmaceuticals
- Flex Pharma
- Collegium Pharmaceutical
- Agile Therapeutics
- Akebia Therapeutics
- Auspex Pharmaceuticals
- Applied Genetic Technologies Corp
- Trevena
- Cara Therapeutics
- Mazor Robotics
- Tetraphase Pharmaceuticals
In addition, Mr. Handrinos’ representative transactions include representing:
- Assurex Health in its US$225 million sale to Myriad Genetics
- Press Ganey in its US$2.35 billion sale to EQT
- Babyganics in its sale to SC Johnson & Son Inc.
- Datto, Inc. in its Series B Preferred Stock Financing
- Jefferies and Barclays in follow-on public offerings by Trevena
- Stifel and Piper in a follow-on public offering by Cara Therapeutics
- BofA Merrill Lynch and Cowen in a follow-on public offering by Dyax Corp.
- UBS and Morgan Stanley in a follow-on offering by Akebia Therapeutics
- Aratana Therapeutics in its:
- PIPE and follow-on offerings
- Acquisition of Okapi Sciences BV
- Acquisition of Vet Therapeutics Inc.
- Radius Health in its follow-on offerings
- BIND Therapeutics in its follow-on offerings
- Morgan Stanley and BAML in a follow-on offering by Sarepta Therapeutics
- BMO and Stifel in follow-on offerings by Tetraphase Pharmaceuticals
- Chiasma in its US$595 million collaboration with Roche
- JP Morgan, Cowen, and Jefferies in a follow-on offering by ARIAD